274 related articles for article (PubMed ID: 31632497)
1. Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.
Ye N; Jiang N; Feng C; Wang F; Zhang H; Bai HX; Yang L; Su Y; Huang C; Wanggou S; Li X
J Cancer; 2019; 10(22):5536-5548. PubMed ID: 31632497
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Otsuji R; Hamada T; Matsuo K; Kirishima M; Hata N; Hanaya R; Tanimoto A; Yoshimoto K
Neurooncol Adv; 2022; 4(1):vdac097. PubMed ID: 35911637
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
Front Oncol; 2019; 9():1433. PubMed ID: 31921684
[No Abstract] [Full Text] [Related]
5. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
6. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
8. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
9.
Kikuchi Z; Shibahara I; Yamaki T; Yoshioka E; Shofuda T; Ohe R; Matsuda KI; Saito R; Kanamori M; Kanemura Y; Kumabe T; Tominaga T; Sonoda Y
Neurooncol Adv; 2020; 2(1):vdaa114. PubMed ID: 33134923
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of
Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
[TBL] [Abstract][Full Text] [Related]
11. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Prognostic Implications of 1p/19q,
Yang Z; Ling F; Ruan S; Hu J; Tang M; Sun X; Long W
Cancer Manag Res; 2021; 13():8755-8765. PubMed ID: 34849029
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
14. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
Front Immunol; 2022; 13():869061. PubMed ID: 36248907
[TBL] [Abstract][Full Text] [Related]
15. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
16. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
[TBL] [Abstract][Full Text] [Related]
18. A Novel Six-mRNA Signature Predicts Survival of Patients With Glioblastoma Multiforme.
Liu Z; Zhang H; Hu H; Cai Z; Lu C; Liang Q; Qian J; Wang C; Jiang L
Front Genet; 2021; 12():634116. PubMed ID: 33790946
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of CBR1 as a prognostic factor associated with IDH-mutant glioblastoma in the Chinese population.
Ji P; Shan X; Wang J; Zhang P; Cai Z
Am J Transl Res; 2022; 14(8):5394-5408. PubMed ID: 36105052
[TBL] [Abstract][Full Text] [Related]
20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]